Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | FLT3 exon 14 ins |
Therapy | Cytarabine + Gilteritinib + Idarubicin |
Indication/Tumor Type | acute myeloid leukemia |
Response Type | predicted - sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
FLT3 exon 14 ins | acute myeloid leukemia | predicted - sensitive | Cytarabine + Gilteritinib + Idarubicin | Phase I | Actionable | In a Phase Ib trial, the addition of Xospata (gilteritinib) to induction and consolidation chemotherapy (cytarabine plus idarubicin or daunorubicin), followed by Xospata (gilteritinib) maintenance was well tolerated and resulted in a composite complete response rate of 89% (32/36) and a median overall survival of 46.1 mo in patients with acute myeloid leukemia harboring FLT3 mutations, including FLT3-ITD and/or D835 mutations (n=25 with FLT3-ITD, 5 with D835, and 10 with both) (PMID: 37379495; NCT02236013). | 37379495 |
PubMed Id | Reference Title | Details |
---|---|---|
(37379495) | Gilteritinib in Combination With Induction and Consolidation Chemotherapy and as Maintenance Therapy: A Phase IB Study in Patients With Newly Diagnosed AML. | Full reference... |